Despite the fact that the biotech sector has faced some setbacks recently, Jay Silverman, editor of Medical Technology Stock Letter, is confident it's only the case of a normal correction.
Steve Halpern: We're here today with biotech sector expert, Jay Silverman, editor of the Medical Technology Stock Letter. How are you doing today, Jay?
Jay Silverman: Very well. Thank you, Steve.
Steve Halpern: After an exceptionally strong performance over the past year, the biotech sector's been noticeably weak in the past weeks or months. Some pundits have been suggesting that the biotech boom may be over, but you've taken a much more measured approach and have seen this weakness as a normal correction. First, you've looked at the technical factors. What do you see there? (more)
Please share this article
No comments:
Post a Comment